A file photo of the Delhi high court. Photo: HT
A file photo of the Delhi high court. Photo: HT

Delhi HC asks Glenmark to stop making Linezolid drug

Symed Laboratories had approached the high court in 2013 seeking to restrain Glenmark for infringing two of its process patent for Linezolid

New Delhi: The Delhi high court on Monday restrained Mumbai-based generic drug maker Glenmark Pharmaceuticals Ltd from manufacturing and selling, directly or indirectly, Linezolid, manufactured through the process patented by the Hyderabad-based pharma company Symed Laboratories Ltd.

Linezolid is a synthetic antibiotic used to treat infections, including pneumonia, and infections of the skin and blood.

Symed had approached the high court in 2013 seeking to restrain Glenmark for infringing two of its process patent for Linezolid.

It had claimed that upon testing samples of Glenmark’s products, it had found two compounds (novel intermediates) which indicated that Glenmark was using Symed’s patented process to manufacture its products.

Denying Symed’s claims, Glenmark argued that it was not infringing Symed’s patent but did not dislclose the process being used by it.

Glenmark could not be reached for comment.

Close